Hookipa Pharma

HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The company is headquartered in New York City, New York and currently employs 82 full-time employees. The company went IPO on 2019-04-18. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers.